NEW YORK, July 25, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prosensa Holding N.V. ("Prosensa" or the "Company") (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
The investigation concerns whether Prosensa and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On September 20, 2013, The Company issued a joint press release with GlaxoSmithKline, disclosing that drisapersen, the Company's first and lead product candidate which Prosensa was developing in collaboration with GlaxoSmithKline, had not met the primary endpoint in the Phase III study. According to the press release, "[t]here was no treatment difference in key secondary assessments of motor function: 10-meter walk/run test, 4-stair climb and North Star Ambulatory Assessment."
On this news, shares of Prosensa fell $16.86 per share to $7.14, or approximately 70%, in intraday trading on September 20, 2013.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
SOURCE Pomerantz LLP
